BIOTRONIK Neuro has acquired a portfolio of spinal cord stimulation intellectual property from Soin Neuroscience, expanding its chronic pain neuromodulation technology platform.

The acquired patents cover spinal cord stimulation waveform design, adaptive programming and the application of machine learning and artificial intelligence to neuromodulation therapy. Financial terms were not disclosed.

This is relevant because chronic pain remains a major clinical and public health challenge, especially as healthcare systems continue to seek alternatives to long-term opioid use. Spinal cord stimulation can help selected patients manage chronic pain, but therapy optimisation remains complex and patient response can vary.

The acquisition builds on a prior research collaboration between Soin Neuroscience and BIOTRONIK Neuro announced in December 2025. That collaboration evaluated novel waveforms and personalised spinal cord stimulation tuning approaches on BIOTRONIK Neuro’s Prospera SCS System.

The strategic value lies in making spinal cord stimulation more personalised and adaptive. Instead of static programming, future systems may use data-driven approaches to better match therapy to individual patient response and changing pain patterns.

Soin Neuroscience will continue to operate independently, with the transaction limited to intellectual property related to the spinal cord stimulation programme. The company’s other research, clinical and business activities are unaffected.

BIOTRONIK Neuro is part of BIOTRONIK, a global medical technology company with a long history in cardiac rhythm management, vascular intervention, electrophysiology and neuromodulation. Its neuromodulation business is based in Lake Oswego, Oregon and includes the Prospera SCS System.